Table 3. Mean MAP reductions with... | American Society of Hematology

Table 3.

Mean MAP reductions with specific BP medications/combinations

	Estimate	95% CI		P value
	Estimate	Lower	Higher	P value
Prior-HTN
ACEi/ARB	−1.30	−4.74	2.13	.45
BBs	−2.06	−5.10	0.97	.18
CCBs	2.33	−0.74	5.41	.13
HCTZ	−1.17	−4.10	1.76	.43
BBs and HCTZ∗	−5.05	−10.0	−0.0596	.047
de novo HTN
ACEi/ARB	−0.13	−3.57	3.31	.94
BBs	−2.71	−6.88	1.45	.20
CCBs	0.11	−5.66	5.90	.96
HCTZ	−4.26	−9.46	0.93	.10
ACEi/ARB and HCTZ∗	−5.47	−10.9	−0.001	.05
All patients combined
ACEi/ARB and HCTZ∗	−3.16	−6.22	−0.10	.04
BBs and HCTZ∗	−5.05	−9.61	−0.48	.03

	Estimate	95% CI		P value
	Estimate	Lower	Higher	P value
Prior-HTN
ACEi/ARB	−1.30	−4.74	2.13	.45
BBs	−2.06	−5.10	0.97	.18
CCBs	2.33	−0.74	5.41	.13
HCTZ	−1.17	−4.10	1.76	.43
BBs and HCTZ∗	−5.05	−10.0	−0.0596	.047
de novo HTN
ACEi/ARB	−0.13	−3.57	3.31	.94
BBs	−2.71	−6.88	1.45	.20
CCBs	0.11	−5.66	5.90	.96
HCTZ	−4.26	−9.46	0.93	.10
ACEi/ARB and HCTZ∗	−5.47	−10.9	−0.001	.05
All patients combined
ACEi/ARB and HCTZ∗	−3.16	−6.22	−0.10	.04
BBs and HCTZ∗	−5.05	−9.61	−0.48	.03

Bold values indicate statistically significant findings.

BP combination was statistically significant after controlling for the possible effects of a single drug class.